1. Home
  2. ABVC vs SILO Comparison

ABVC vs SILO Comparison

Compare ABVC & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ABVC BioPharma Inc.

ABVC

ABVC BioPharma Inc.

HOLD

Current Price

$1.04

Market Cap

30.9M

Sector

Health Care

ML Signal

HOLD

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.35

Market Cap

4.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABVC
SILO
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
30.9M
4.6M
IPO Year
2009
2011

Fundamental Metrics

Financial Performance
Metric
ABVC
SILO
Price
$1.04
$0.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
48.5K
181.7K
Earning Date
03-03-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
7.14
57.98
EPS
N/A
N/A
Revenue
$509,589.00
$72,102.00
Revenue This Year
N/A
$1.86
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.22
52 Week High
$4.02
$1.18

Technical Indicators

Market Signals
Indicator
ABVC
SILO
Relative Strength Index (RSI) 35.36 49.34
Support Level N/A $0.33
Resistance Level $1.67 $0.39
Average True Range (ATR) 0.12 0.03
MACD -0.01 -0.00
Stochastic Oscillator 29.19 49.40

Price Performance

Historical Comparison
ABVC
SILO

About ABVC ABVC BioPharma Inc.

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

Share on Social Networks: